Literature DB >> 7855907

Non-opioid effects of dynorphins: possible role of the NMDA receptor.

V K Shukla1, S Lemaire.   

Abstract

Dynorphin A (dynA) and related opioid peptides produce moderate analgesic effects with restricted types of pain stimuli that are often accompanied by a large variety of naloxone-insensitive biochemical and behavioural effects. In binding assays in vitro, dynA possesses a high affinity for mu-, delta- and kappa- opioid receptors with some selectivity for kappa sites, but it also binds to specific non-opioid sites. The involvement of the NMDA receptor has been suggested to explain some of the non-opioid effects of dynA and related peptides. In this article, Vijay Shukla and Simon Lemaire review the experimental evidence that suggests a role for the NMDA receptor in some of the pharmacological effects of dynA and related peptides.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7855907     DOI： 10.1016/0165-6147(94)90091-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  21 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Paradoxical hyperalgesia induced by mu-opioid receptor agonist endomorphin-2, but not endomorphin-1, microinjected into the centromedial amygdala of the rat.

Authors:  Maia Terashvili; Hsiang-En Wu; Emma Schwasinger; Leon F Tseng
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

Review 3.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

Review 4.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

5.  Dynorphin up-regulation in the dentate granule cell mossy fiber pathway following chronic inhibition of GluN2B-containing NMDAR is associated with increased CREB (Ser 133) phosphorylation, but is independent of BDNF/TrkB signaling pathways.

Authors:  W Bradley Rittase; Yu Dong; DaRel Barksdale; Zygmunt Galdzicki; Suzanne B Bausch
Journal:  Mol Cell Neurosci       Date:  2014-04-23       Impact factor: 4.314

6.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

7.  Metabolism of dynorphin A1-13 in human CSF.

Authors:  S Müller; B L Grundy; G Hochhaus
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

8.  Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons.

Authors:  K F Hauser; J K Foldes; C S Turbek
Journal:  Exp Neurol       Date:  1999-12       Impact factor: 5.330

9.  Dynorphin peptides: antagonists of melanocortin receptors.

Authors:  J M Quillan; W Sadée
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

Review 10.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.